Ahmad S, Orellana A, Kohler I, et al. - This study was undertaken to determine if lysophosphatidic acids (LPAs) are correlated with Alzheimer disease (AD) pathology and progression from mild cognitive impairment (MCI) to AD. The current study was conducted using the cerebrospinal fluid (CSF) and plasma samples from 182 MCI patients from two independent cohorts. According to results, five LPAs (C16:0, C16:1, C22:4, C22:6, and isomer-LPA C22:5) exhibited a significant positive correlation with CSF biomarkers of AD, Aβ-42, p-tau, and total tau. LPA C14:0 and C20:1 were only associated with Aβ-42 and alkyl-LPA C18:1, and LPA C20:1 is associated with tau pathology biomarkers. The results provide evidence that LPAs may contribute to the pathogenesis of early AD. In order to determine whether LPAs play a role in upstream AD pathology or are downstream neurodegeneration markers, future studies are required.